- Home
- KZIA vs NERV Comparison
KZIA vs NERV Comparison
Compare KZIA & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KZIA | NERV |
|---|---|---|
| Founded | 1994 | 2007 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.7M | 166.4M |
| IPO Year | 2002 | 2014 |
Fundamental Metrics
Financial Performance| Metric | KZIA | NERV |
|---|---|---|
| Price | $8.06 | $2.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $28.33 | $10.33 |
| AVG Volume (30 Days) | ★ 248.3K | 106.1K |
| Earning Date | 11-06-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.86 | $2.24 |
| 52 Week High | $17.40 | $8.80 |
Technical Indicators
Market Signals| Indicator | KZIA | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 39.10 | 28.32 |
| Support Level | $6.72 | N/A |
| Resistance Level | $8.18 | $5.69 |
| Average True Range (ATR) | 0.67 | 0.26 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 48.51 | 9.85 |
Price Performance
Historical ComparisonAbout KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.